Evidence map›Paper›PMID 39939364›Full record

SynthesisProstate cancer and prostatic diseases2026

Is there a role of PSMA-PET in focal therapy planning and follow-up?

Rossella Nicoletti, Andrea Alberti, Vineet Gauhar, Elena Ciaralli, Chi Hang Yee, Peter Chiu, David Leung, Daniele Castellani, Theodoros Tokas, Bhaskar Somani and 8 more

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Prostate cancer and prostatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Prostate specific membrane antigen focal ablation imaging (PSMA-FAB).Prostate cancer and prostatic diseases · 2026
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Rossella Nicoletti *Unit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy.ORCID http://orcid.org/0000-0001-6898-7698
Andrea Alberti *Unit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy.ORCID http://orcid.org/0000-0002-8988-0133
Vineet GauharNg Teng Fong General Hospital, NUHS, Singapore, Singapore.ORCID http://orcid.org/0000-0002-3740-7141
Elena CiaralliUnit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy.
Chi Hang YeeS.H.Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.ORCID http://orcid.org/0000-0001-6557-3107
Peter ChiuS.H.Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.ORCID http://orcid.org/0000-0002-1499-8372
David LeungS.H.Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.
Daniele CastellaniUrology Unit, Azienda Ospedaliero-Universitaria delle Marche, Università Politecnica delle Marche, Ancona, Italy.ORCID http://orcid.org/0000-0001-7354-9190
Theodoros TokasDepartment of Urology, University General Hospital of Heraklion, University of Crete, Medical School, Heraklion, Greece.ORCID http://orcid.org/0000-0003-0928-0507
Bhaskar SomaniUniversity Hospital Southampton NHS Trust, Southampton, UK.ORCID http://orcid.org/0000-0002-6248-6478
Francesco SessaUnit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy.
Dmitry EnikeevRabin Medical Center (Belenson, Hasharon), Petah Tikva, Israel.ORCID http://orcid.org/0000-0001-7169-2209
Nikhil VasdevHertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, Stevenage, UK.
Sergio SerniUnit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy.
Riccardo CampiUnit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy.ORCID http://orcid.org/0000-0001-5237-0888
Mauro GacciUnit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy.
Antony Chi Fai NgS.H.Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.ORCID http://orcid.org/0000-0002-1723-9646
Jeremy Yuen Chun TeohS.H.Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. jeremyteoh@surgery.cuhk.edu.hk.ORCID http://orcid.org/0000-0002-9361-2342

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFocal therapy (FT) is a promising alternative to radical treatments for localized Prostate Cancer (PCa) in selected patients. However, it is not yet considered a standard treatment option, and there is currently no consensus on managing patients after FT. In this context, Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) may support multiparametric MRI (mpMRI) for both pre-operative planning and follow-up. The aim of this systematic review was to provide a comprehensive overview of the current applications of PSMA-PET in the field of FT and to analyze its future perspectives. EVIDENCE ACQUISITION: A literature search was performed using PubMed and Scopus databases, following the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement recommendations. All studies reporting data on PSMA-PET performed before and/or after FT for PCa were included. A narrative synthesis was employed to summarize the review findings. No quantitative synthesis was performed due to the heterogeneity and limitations of the studies. EVIDENCE SYNTHESIS: Seven studies (2 case reports, 1 retrospective, and 4 prospective single-center studies) were included in this review. A moderate-severe risk of bias was assessed for the included studies. In the field of FT, PSMA-PET showed promising but yet not validated results with several possible applications: (1) pre-operative planning and staging, aiming to improve patient selection trough the identification of intraprostatic suspected lesions and more accurate local and systemic staging; (2) guidance for biopsy and Region of Interest (ROI) definition; (3) follow-up imaging tool, aiming to decrease the number of unnecessary surveillance biopsies.

conclusionsLimited evidence exists regarding the use of PSMA-PET in the field of FT, considering pre-operative setting, treatment guidance and its use as a non-invasive tool to evaluate treatment success or failure and for follow-up. In this scenario, even if the current evidence is still limited and inconclusive, PSMA-PET showed promising results with several possible applications.

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IIPositron-Emission TomographyProstatic NeoplasmsFollow-Up StudiesHumansMaleAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase II

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.